Analysts expect surge in profit for Aventis; gain of about 40% seen for first nine months
Article Abstract:
Aventis is in talks to sell its non-core businesses and might also be entertaining pharmaceutical acquisitions. These plans plus strong drug sales collectively put its net profits and forecasts in a good position going forward. Its best-selling drugs are Lovenox, Taxotere and Allegra.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
Sanofi outlines plan to revamp Aventis: suitor would overhaul research and development to boost lab productivity
Article Abstract:
Sanofi S.A. officials have targeted Aventis S.A.'s research and development unit as a candidate for reorganization provided Sanofi is able to acquire the company. The production of vaccines and oncology drugs would be emphasized.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Bayer is changing its prescription for a turnaround
Article Abstract:
Bayer may enter a life sciences contract with a partner to instigate a turnaround for the company. The partner has not been identified.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Unilever profit soars 26%, aided by sale of unit. Fiat changes board, sees more troubles. Car division of Fiat swings to operating profit
- Abstracts: Food for thought. Developing a taste for acquisitions
- Abstracts: ABB's 10% rise in net profit disappoints. ABB tops forecasts, lifts net 17%, boosting shares. Influential chairman quits engineering giant ABB
- Abstracts: ING plans to cut about 1,600 jobs at its U.S. business. Bipop cuts profit on provisions for bad loans. Fortis cuts forecast for full-year earnings
- Abstracts: Skandia gives opposing view room in plan. Aegon may seek acquisition in U.S. Skandia of Sweden creates three units, shuffles executives